Suppr超能文献

对青霉素速发型超敏反应患者中头孢菌素的交叉反应性和耐受性

Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins.

作者信息

Romano Antonino, Guéant-Rodriguez Rosa-Maria, Viola Marinella, Pettinato Rosa, Guéant Jean-Louis

机构信息

Università Cattolica del Sacro Cuore, Complesso Integrato Columbus, Rome, Italy.

出版信息

Ann Intern Med. 2004 Jul 6;141(1):16-22. doi: 10.7326/0003-4819-141-1-200407060-00010.

Abstract

BACKGROUND

In patients with documented IgE-mediated hypersensitivity to penicillins, data on sensitization to cephalosporins vary. Administering cephalosporins to such patients is often deferred because of the risk for cross-reactivity.

OBJECTIVE

To assess the cross-reactivity with cephalosporins and its potential determinants in patients with documented penicillin allergy.

DESIGN

Prospective study in patients without clinical indications for cephalosporin treatment.

SETTING

Italy.

PATIENTS

128 consecutive patients who sustained anaphylactic shock (n = 81) or urticaria (n = 47) and had positive results on skin tests for at least 1 of the penicillin reagents tested.

MEASUREMENTS

All patients were skin tested with cephalothin, cefamandole, cefuroxime, ceftazidime, ceftriaxone, and cefotaxime. Patients with negative results for the last 4 cephalosporins were challenged with cefuroxime axetil and ceftriaxone.

RESULTS

14 patients (10.9% [95% CI, 6.1% to 17.7%]) had positive results on skin tests for cephalosporins, mostly for cephalothin or cefamandole. Skin test results for the minor determinant mixture were positive in 10 of 14 patients (71.4%) with cross-reactivity and 44 of 114 patients (38.6%) without cross-reactivity (odds ratio, 3.90 [CI, 1.17 to 13.40]; P = 0.0189). All 101 patients with negative results on skin tests for cefuroxime, ceftazidime, ceftriaxone, and cefotaxime tolerated cefuroxime axetil and ceftriaxone (tolerability rate, 100% [CI, 96.4% to 100%]).

LIMITATIONS

Challenges were not followed by full therapeutic courses. Twenty-two patients declined challenges; positive responses in those patients would have decreased the tolerability rate to 82.1% (CI, 74.2% to 88.4%).

CONCLUSIONS

These data confirm the advisability of avoiding cephalosporin treatment in patients with positive results on skin tests for penicillin. In patients who especially require cephalosporin treatment, we recommend skin tests with cephalosporins before assessing the tolerability of the cephalosporin with a graded challenge.

摘要

背景

在有记录表明对青霉素存在IgE介导的超敏反应的患者中,对头孢菌素致敏的数据存在差异。由于存在交叉反应的风险,此类患者通常推迟使用头孢菌素。

目的

评估有记录的青霉素过敏患者中与头孢菌素的交叉反应及其潜在决定因素。

设计

对无头孢菌素治疗临床指征的患者进行前瞻性研究。

地点

意大利。

患者

128例连续发生过敏性休克(n = 81)或荨麻疹(n = 47)且对至少一种所检测的青霉素试剂皮肤试验呈阳性的患者。

测量

所有患者均用头孢噻吩、头孢孟多、头孢呋辛、头孢他啶、头孢曲松和头孢噻肟进行皮肤试验。对后4种头孢菌素皮肤试验结果为阴性的患者用头孢呋辛酯和头孢曲松进行激发试验。

结果

14例患者(10.9%[95%CI,6.1%至17.7%])头孢菌素皮肤试验呈阳性,主要针对头孢噻吩或头孢孟多。14例有交叉反应的患者中有10例(71.4%)次要决定簇混合物皮肤试验结果为阳性,114例无交叉反应的患者中有44例(38.6%)呈阳性(比值比,3.90[CI,1.17至13.40];P = 0.0189)。头孢呋辛、头孢他啶、头孢曲松和头孢噻肟皮肤试验结果为阴性的101例患者对头孢呋辛酯和头孢曲松耐受(耐受率,100%[CI,96.4%至100%])。

局限性

激发试验后未进行完整的治疗疗程。22例患者拒绝激发试验;这些患者中的阳性反应会使耐受率降至82.1%(CI,74.2%至88.4%)。

结论

这些数据证实了对青霉素皮肤试验呈阳性的患者避免使用头孢菌素治疗的合理性。对于特别需要头孢菌素治疗的患者,我们建议在通过分级激发试验评估头孢菌素的耐受性之前,先用头孢菌素进行皮肤试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验